These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35570237)

  • 21. Distribution and relation of two arm function tests, Box and Blocks test and Nine Hole Peg test, across disease severity levels and types of multiple sclerosis.
    Bertoni R; Cattaneo D; Grosso C; Baglio F; Jonsdottir J
    Mult Scler Relat Disord; 2022 Mar; 59():103683. PubMed ID: 35168094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The natural history of early versus late disability accumulation in primary progressive MS.
    Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
    Hernandez L; O'Donnell M; Postma M;
    Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 3meter Timed Tandem Walk is an early marker of motor and cerebellar impairment in fully ambulatory MS patients.
    Stellmann JP; Vettorazzi E; Poettgen J; Heesen C
    J Neurol Sci; 2014 Nov; 346(1-2):99-106. PubMed ID: 25156343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.
    Camara-Lemarroy C; Silva C; Gohill J; Yong VW; Koch M
    Eur J Neurol; 2023 Jan; 30(1):187-194. PubMed ID: 36214614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data.
    Goldman MD; LaRocca NG; Rudick RA; Hudson LD; Chin PS; Francis GS; Jacobs A; Kapoor R; Matthews PM; Mowry EM; Balcer LJ; Panzara M; Phillips G; Uitdehaag BMJ; Cohen JA;
    Neurology; 2019 Nov; 93(21):e1921-e1931. PubMed ID: 31641014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The nine hole peg test as an outcome measure in progressive MS trials.
    Koch MW; Repovic P; Mostert J; Bowen JD; Comtois J; Strijbis E; Uitdehaag B; Cutter G
    Mult Scler Relat Disord; 2023 Jan; 69():104433. PubMed ID: 36462470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple sclerosis impairment scale and brain MRI in secondary progressive multiple sclerosis.
    Theodorsdottir A; Larsen PV; Nielsen HH; Illes Z; Ravnborg MH
    Acta Neurol Scand; 2022 Mar; 145(3):332-347. PubMed ID: 34799851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modelling the natural history of primary progressive multiple sclerosis.
    Harding KE; Wardle M; Moore P; Tomassini V; Pickersgill T; Ben-Shlomo Y; Robertson NP
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):13-9. PubMed ID: 24828900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Composite end points to assess delay of disability progression by MS treatments.
    Zhang J; Waubant E; Cutter G; Wolinsky J; Leppert D
    Mult Scler; 2014 Oct; 20(11):1494-501. PubMed ID: 24675040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial.
    Harris VK; Stark J; Williams A; Roche M; Malin M; Kumar A; Carlson AL; Kizilbash C; Wollowitz J; Andy C; Gerber LM; Sadiq SA
    Stem Cell Res Ther; 2024 May; 15(1):151. PubMed ID: 38783390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.
    Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA
    Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain grey matter perfusion in primary progressive multiple sclerosis: Mild decrease over years and regional associations with cognition and hand function.
    Testud B; Delacour C; El Ahmadi AA; Brun G; Girard N; Duhamel G; Heesen C; Häußler V; Thaler C; Has Silemek AC; Stellmann JP
    Eur J Neurol; 2022 Jun; 29(6):1741-1752. PubMed ID: 35167161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment.
    Wasem J; Heer Y; Karamasioti E; Muros-Le Rouzic E; Marcelli G; Di Maio D; Braune S; Kobelt G; Dillon P
    Pharmacoecon Open; 2024 Sep; 8(5):665-678. PubMed ID: 38949748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS.
    Bosma L; Kragt JJ; Polman CH; Uitdehaag BM
    Mult Scler; 2013 Mar; 19(3):326-33. PubMed ID: 22907939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Smoking does not influence disability accumulation in primary progressive multiple sclerosis.
    Javizian O; Metz LM; Deighton S; Koch MW
    Eur J Neurol; 2017 Apr; 24(4):624-630. PubMed ID: 28239937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EDSS variability before randomization may limit treatment discovery in primary progressive MS.
    Zhang J; Waubant E; Cutter G; Wolinsky JS; Glanzman R
    Mult Scler; 2013 May; 19(6):775-81. PubMed ID: 23027880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlates of the timed 25 foot walk in a multiple sclerosis outpatient rehabilitation clinic.
    Bethoux FA; Palfy DM; Plow MA
    Int J Rehabil Res; 2016 Jun; 39(2):134-9. PubMed ID: 26926380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebellar pathology and disability worsening in relapsing-remitting multiple sclerosis: A retrospective analysis from the CombiRx trial.
    Petracca M; Cutter G; Cocozza S; Freeman L; Kangarlu J; Margoni M; Moro M; Krieger S; El Mendili MM; Droby A; Wolinsky JS; Lublin F; Inglese M
    Eur J Neurol; 2022 Feb; 29(2):515-521. PubMed ID: 34695274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
    Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.